SCHEDULE: FMR LLC Discloses 9.9% Stake in Centessa Pharmaceuticals

FMR LLC and its affiliates, including Abigail P. Johnson, reported a 9.9% beneficial ownership stake in Centessa Pharmaceuticals PLC as of December 31, 2025.

Summary

• FMR LLC, a parent holding company, and Abigail P. Johnson, an individual, beneficially own 8,894,939 shares of Centessa Pharmaceuticals PLC common stock.
• This ownership represents 9.9% of the total outstanding common stock of Centessa Pharmaceuticals PLC.
• FMR LLC holds sole voting power and sole dispositive power over all 8,894,939 shares.
• Abigail P. Johnson holds sole dispositive power over the same 8,894,939 shares, reflecting her control over FMR LLC.
• The securities were acquired and are held in the ordinary course of business and not for the purpose of changing or influencing the control of Centessa Pharmaceuticals PLC.
• FMR LLC's subsidiaries, including FIAM LLC, Fidelity Institutional Asset Management Trust Company, and Fidelity Management & Research Company LLC, are identified as relevant entities beneficially owning shares.

Sentiment

Score: 7

Explanation: StockSavvy.ai views this as a moderately positive development, as a significant stake by a reputable institutional investor like FMR LLC generally signals confidence in the company's prospects, though the filing itself does not provide operational or financial performance details.

Positives

• A significant 9.9% stake by a major institutional investor like FMR LLC (Fidelity) can be interpreted as a vote of confidence in Centessa Pharmaceuticals PLC's long-term prospects and strategic direction.
• The disclosure indicates strong institutional interest in Centessa Pharmaceuticals PLC, potentially attracting further investor attention.

Future Outlook

NA

Management Comments

• FMR LLC and Abigail P. Johnson certify that the securities were acquired and are held in the ordinary course of business and were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of Centessa Pharmaceuticals PLC, and were not acquired and are not held in connection with or as a participant in any transaction having that purpose or effect, other than activities solely in connection with a nomination under Rule 240.14a-11.

Industry Context

StockSavvy.ai notes that FMR LLC, a prominent asset management firm, maintaining a significant 9.9% stake in Centessa Pharmaceuticals PLC underscores continued institutional confidence in the biotechnology and pharmaceutical sectors. This level of ownership by a major player like Fidelity often signals a belief in the long-term value proposition of the company's drug pipeline or strategic direction, aligning with broader trends of institutional investment in innovative healthcare companies.

Comparison to Industry Standards

• A 9.9% beneficial ownership stake by an institutional investor like FMR LLC is substantial and typically places them among the top shareholders of a publicly traded company.
• This level of ownership is common for large asset managers who take significant positions in companies they believe have strong growth potential, similar to how Vanguard or BlackRock might hold large stakes in pharmaceutical giants like Pfizer or emerging biotechs like Moderna during their growth phases.
• While not a controlling stake, it represents a material investment that can influence market perception and potentially provide a stable shareholder base for Centessa Pharmaceuticals PLC, comparable to the institutional backing seen in successful biotech ventures.

Stakeholder Impact

• Shareholders may view this as a positive signal, potentially increasing investor confidence and demand for Centessa Pharmaceuticals PLC's stock.
• The presence of a large institutional investor can provide a degree of stability to the company's shareholder base.

Key Dates

Keywords

Centessa Pharmaceuticals, FMR LLC, Abigail P. Johnson, Beneficial Ownership, Institutional Investor, Pharmaceuticals, Biotech, SEC Filing, Schedule 13G, Common Stock